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The main objective of the study was to enhance the dissolution of nifedipine, a poorly water soluble 
drug by betacyclodextrin complexation and to study the effect of the preparation method on the in 
vitro dissolution profile. The stoichiometric ratio determined by phase solubility analysis for inclusion 
complexation of nifedipine with β-cyclodextrin was 1:1. Binary complex was prepared by different 
methods and was further characterized using XRD, DSC and FT-IR. A saturation solubility study was 
carried out to evaluate the increase in solubility of nifedipine. The optimized complex was formulated into 
fast-dissolving tablets by using the superdisintegrants Doshion P544, pregelatinized starch, crospovidone, 
sodium starch glycolate and croscarmellose sodium by direct compression. Tablets were evaluated for 
friability, hardness, weight variation, disintegration and in vitro dissolution. Tablets showed an enhanced 
dissolution rate compared to pure nifedipine.
Uniterms: Fast-dissolving tablets. Nifedipine/dissolution. β-ciclodextrin/complexation. Superdisintegrants.
Este estudo teve por objetivo principal incrementar a dissolução do nifedipino, fármaco pouco solúvel 
em água, por meio de sua complexação com b-ciclodextrina e estudar o efeito do método de preparação 
sobre o perfil de dissolução in vitro. A razão estequiométrica, determinada por ensaio de solubilidade 
de fase, para a complexação de nifedipino por inclusão em β-ciclodextrina foi 1:1. O complexo binário 
foi preparado por diferentes métodos, sendo caracterizado utilizando-se difratometria de raios X (XRD), 
calorimetria diferencial de varredura (DSC) e espectroscopia no infravermelho com transformada de 
Fourier (FT-IR). Realizou-se estudo de solubilidade de saturação para avaliar o incremento da solubilidade 
do nifedipino. O complexo otimizado foi formulado em comprimidos de dissolução rápida preparados por 
compressão direta, nos quais se utilizaram os superdesintegrantes Doshion P544, amido pré-gelatinizado, 
crospovidona, amidoglicolato de sódio e croscarmelose sódica. Os comprimidos, que foram avaliados 
quanto à friabilidade, dureza, variação de peso, desintegração e dissolução in vitro, apresentaram taxa 
de dissolução superior à do nifedipino pura.
Unitermos: Comprimidos/de dissolução rápida. Nifedipino/dissolução. β-ciclodextrina/complexação. 
Superdesintegrantes.
INTRODUCTION
Nifedipine is an oral calcium-channel blocking 
agent, widely used in the treatment of angina pectoris 
and hypertension. Nifedipine is a poorly water-soluble 
drug and its oral bioavailability is very low. Diseases like 
angina, asthma, epilepsy etc. require immediate drug re-
sponse to manage the disease condition. Improvement of 
the aqueous solubility of poorly water-soluble drugs is one 
of the important factors for the enhancement of absorption 
and obtaining adequate oral bioavailability (Hiroyuki et 
al., 2009).
Cyclodextrins (CDs) have been used extensively as 
additives to increase the solubility of poorly water-soluble 
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organic compounds, by the formation of an inclusion 
complex between the host cyclodextrin molecules and 
guest molecules. The resulting noncovalent inclusions or 
host-guest complexes are of current scientific and techno-
logical interest for their peculiar physical, chemical and 
biological properties. Such noncovalent associations can 
actually improve the guest’s water solubility, bioavail-
ability and stability, as well as regulate the release of the 
guest molecules (Chao et al., 2008).
The dissolution of a drug can also be influenced 
by disintegration time of tablets. Faster disintegration of 
tablets delivers a fine suspension of drug particles result-
ing in a higher surface area and faster dissolution. Most 
commonly used methods to prepare fast dissolving tablets 
are; freeze-drying, tablet moulding and direct compres-
sion methods. Lyophilized tablets possess a very porous 
structure, which causes quick penetration of saliva into 
the pores when placed in the oral cavity. Moulded tablets 
dissolve completely and rapidly. However lack of strength 
and taste masking are of great concern. Main advantages 
of direct compression are low manufacturing cost and 
high mechanical integrity of tablets. Therefore, direct 
compression appears to be better option for manufacturing 
of tablets. Fast disintegrating tablets prepared by the direct 
compression method, in general, are based on the action 
established by various superdisintegrants. The effect of 
functionality differences in superdisintegrants on tablet 
disintegration has been previously studied (Setty, 2008).
MATERIAL AND METHODS
Material
Nifedipine was a generous gift from Alkem Lab 
(Mumbai). The drug was stored in an amber glass con-
tainer wrapped with aluminium foil and kept in a refrig-
erator at 5–7 °C. The complexing agent betacyclodextrin 
(BCD) was purchased from Gangwal chemicals, Mumbai. 
Microcrystalline cellulose (MCC), mannitol, aspartame, 
magnesium stearate, orange flavor, pregelatinized starch, 
sodium starch glycolate, crospovidone, Doshion P 544 
and croscarmellose sodium were procured from SD fine 
chemicals, Mumbai. All other chemicals and solvents 
used were of pharmaceutical and analytical grade. Double 
distilled water was used throughout the study for all the 
experimental procedures.
Phase solubility study
Phase solubility studies were carried out at room 
temperature, in triplicate and according to the method 
reported by Higuchi and Connors (Higuchi, 1965). An 
excess amount of nifedipine was added to double distilled 
water containing various concentrations of β-CD (0.02-
0.1 M) in a series of stoppered conical flasks and shaken 
for 48 h on a rotary flask shaker. The suspensions were 
filtered through Whatman filter paper and assayed for 
nifedipine using a UV spectrophotometer (Varian Cary 
100, Australia) at 238 nm against a blank prepared using 
the same concentration of β-CD in double distilled water.
Preparation of nifedipine: b-CD complexes [1:1 
Molar ratio]
The solid complexes of nifedipine and β-CD (1:1 
molar ratio) were prepared by the following method-
Kneading method (Kn)
Drug and β-CD was triturated in a mortar with a 
small volume of water-methanol solution. The thick slurry 
was kneaded for 45 min and then dried at 40 0C. Dried 
mass was pulverized and sieved through a (#100) mesh 
(Nalluri et al., 2005).
Coevaporation method (COE)
The aq. solution of β-CD was added to an alcoholic 
solution of drug. The resulting mixture was stirred for 1 
hr and evaporated at a temp of 450C until dry. The dried 
mass was pulverized and sieved through a (#100) mesh 
(Nalluri et al., 2005).
Co-grounding (COG)
Drug was triturated with a minimal quantity of 
methanol in a glass mortar until dissolved. β-CD was then 
added and the suspension triturated rapidly at room tem-
perature until solvent had evaporated (Friedrich, 2005).
Freeze –Drying Method (FD)
Physical mixtures of drug and β-CD at a molar 
ratio of 1:1 were added to 500 ml double distilled water 
and stirred for 5 days. The suspension was freeze-dried 
(ilshin® freeze Dryer), and the freeze-dried complex thus 
produced was pulverized and sieved through a (<38µm) 
mesh (Tsinontides et al., 2004).
Melting method (MELT)
A melting method was used for the preparation of 
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drug- β-CD complex. The drug- β-CD ratio (1:1 Molar) 
was accurately weighed, mixed in s crucible, and the mix-
ture kept for melting in a water bath with constant stirring. 
The mixture was cooled slowly at room temperature. The 
product was placed in desiccators. The solidified product 
was transferred to a clean mortar, triturated and passed 
through sieves no.16 and 20 (Van et al., 1998).
Physical mixture (PM)
The physical mixtures of nifedipine and β-CD [1:1 
molar ratio] were obtained by mixing pulverized powder 
(#100) together in pestle and mortar (Nalluri et al., 2005).
Spray Drying method (SPD)
A mixture of drug and β-CD was dissolved in 250 
ml of water. The resultant solution was spray dried using 
a spray dryer. The spray drying was done under the fol-
lowing sets of conditions; air flow rate at 400 Nl/h, spray 
nozzle with a diameter 0.7 mm under an atomization pres-
sure of 2 kg/cm2 with a feed rate of 4 mL/min. The inlet 
temperature was kept at 120 °C and out let temperature at 
90 °C ± 2 °C. The vacuum in the system was 60 mmWc 
and the aspiration rate was 40 m Bar. The product thus 
obtained was collected, packed, doubly wrapped in alumi-
num foil and stored in a desiccator until further use (Patil 
et al., 2010).
Evaluation of solid complexes
Determination of drug content
Drug: b-CD complex equivalent to 10 mg of drug 
was stirred with 100ml of methanol for 60 minutes. Sub-
sequently, the solution was filtered and treated as stock 
solution containing 100 μg/mL drug. From this stock 
solution a concentration of 10 μg/mL was prepared and 
the drug content determined using the calibration curve of 
pure drug in methanol, analyzed spectrophotometrically 
at 238 nm using methanol as the blank (Shirsand, 2010).
Saturation solubility studies
A saturation solubility study was carried out to deter-
mine increase in the solubility of pure nifedipine compared 
with the PM and inclusion complexes. Excess amount 
of the drug, PM and inclusion complexes were added to 
the 250 mL conical flasks containing 25 mL of double 
distilled water. The sealed flasks were shaken for 24 h at 
room temperature followed by equilibrium for three days. 
Aliquots were then withdrawn through Whatman filter 
paper. The concentration of nifedipine was determined by 
UV spectrophotometer at 238 nm (Vanshiv, 2008).
Characterization of nifedipine:b-CD (1:1) 
complexes
UV spectroscopic study
Complex formation between nifedipine and CD was 
studied by the UV spectroscopic method. 10mg amounts 
of nifedipine were weighed accurately and dissolved in 
100ml of methanol, diluted suitably and spectra of drug 
recorded at 238 nm. The same method was used only 
nifedipine - CD complex equivalent to 10 mg of nifedip-
ine were weighed accurately and dissolved in 100 mL 
of methanol, diluted suitably and spectra of complexes 
recorded at 238 nm. The change in the absorbance of drug 
in the complexes was recorded.
Fourier Transform Infrared spectrophotometry [FT-IR]
FT-IR has been employed as a useful tool to identify 
drug excipient interaction. Samples were analyzed by the 
potassium bromide pellet method in an IR spectropho-
tometer (Varian, Australia) in the region from 4000 to 
400 cm-1. Complex formation was evaluated by comparing 
the IR spectra of the solid complex and that of the drug. 
Powder X-ray Diffractometry [PXRD]
The powder X-ray diffraction technique has been 
extensively utilized along with DSC to study the interac-
tion between drug and β-CD . The diffraction studies were 
carried out on a powder X-ray diffractometer (STOE-
STADI-P). The samples were rotated during data collec-
tion to reduce orientation effects. PXRD patterns of solid 
complex, pure drug, and β-CD were recorded between 
2θ = 5 to 50° at 40 kV and 30 mA.
Differential Scanning Calorimetry [DSC]
Differential scanning calorimetry (DSC) has been 
one of the most widely used calorimetric techniques to 
study the solid state interaction of drug with β-CD (Ra-
mana et al.,2008). Samples of the solid complexes, pure 
drug, and β-CD were taken in flat-bottomed aluminium 
pans and heated over a temperature range of 25 to 300 °C 
at a constant rate of 10°/min with purging of nitrogen 
(50 ml/min) using alumina as a reference standard in a 
differential scanning calorimeter (DSC-7, Perkin Elmer).
In-vitro dissolution studies
Drug release studies were performed in triplicate at 
37 ± 0.5 0C employing USP apparatus II at 75 rpm. The 
dissolution study was carried out in two dissolution media 
(Phosphate buffer of pH 6.8 and double distilled water). 
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Dissolution studies were performed on pure drug (10 mg) 
and the complexes containing an equivalent amount of 
the drug. Aliquots of the periodically withdrawn samples 
(5 mL) were analyzed spectrophotometrically at 238 nm, 
and replaced with an equal volume of plain dissolution 
medium (Naveen, 2007).
Formulation of tablets
Freeze-dried complex was selected for the formula-
tion of tablets. Tablets containing 42.8 mg of drug:b-CD 
freeze dried complex equivalent to 10 mg of drug were 
prepared by the direct compression method and the vari-
ous formulae used in the study are shown in Table I. The 
drug, diluents, superdisintegrant and sweetener were 
passed through sieve ≠ 40. All the above ingredients were 
properly mixed together (in a polybag). Magnesium stea-
rate was passed through sieve ≠ 80, mixed, and blended 
with the initial mixture in a polybag. The powder blend 
was compressed into tablets on an 8-station Rotary Tablet 
Machine Minipress-II (Rimek Ltd.). The weight of tablets 
in each batch was kept constant (Setty, 2008).
Evaluation of fast-dissolving tablets
Evaluation of powder blend
The powder blend was evaluated for flow proper-
ties. Different tests carried out included bulk density, 
tapped density, compressibility index, and Hausner ratio 
(Lachman, 1991).
 (1)
  (2)
  (3)
  (4)
Evaluation of tablets
Hardness of the tablets was evaluated using a Mon-
santo hardness tester. The friability of tablets for each 
batch was determined using an automated USP Roche 
friabilator. The Tablets were subjected to tests for uni-
formity of drug content, and uniformity of mass of single 
dose preparation as per US Pharmacopeia (USP, 2009).
In vitro disintegration, wetting time and water 
absorption ratio studies
For determination of in vitro disintegration time 
(D.T.), one tablet was placed in a beaker containing 10ml 
of phosphate buffer at pH 6.8 and the time required for 
complete dissolution (with mild shaking) was measured 
(Kimura, 1992). On the other hand, the wetting time was 
measured as follows: a sample of the final tablet was 
placed in a petri dish (10 cm in diameter) containing 10 mL 
TABLE I - Formulae used in the preparation of tablets
Ingredients (mg) Control DO I DO II DO III PGS I PGS II PGS III CRP I CRP II CRP III SSG I SSG II SSG III CCS I CCS II CCS III 
Drug : CD 
Complex
42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8 42.8
MCC PH 102 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2 83.2
Mannitol 120 104.4 99.2 94 104.4 99.2 94 104.4 99.2 94 104.4 99.2 94 104.4 99.2 94
Doshion P544 - 15.6 20.8 26.0 - - - - - - - - - - - -
Crospovidone - - - - - - - 15.6 20.8 26.0 - - - - - -
Croscarmellose 
Sodium
- - - - - - - - - - - - - 15.6 20.8 26.0
Pregelatinized 
starch
- - - - 15.6 20.8 26.0 - - - - - - - - -
Sodium starch 
glycolate
- - - - - - - - - - 15.6 20.8 26.0 - - -
Aspartame 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Magnesium 
stearate
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Orange Flavor 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Total ( mg) 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260
DO-Doshion, PGS-Pregelatinized starch, CRP-Crospovidone, SSG-Sodium starch Glycolate, CCS-Croscarmellose sodium, I-6%, II-8%, III-10%
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of water at room temperature. The wetting time is the 
period necessary for complete wetting of the tablet. The 
wetted tablet was then weighed. Water absorption ratio, 
R, was determined according to the following equation: 
  (5)
where Wa and Wb are the weights before and after water 
absorption, respectively (Shirsand et al., 2008).
In vitro dissolution
In vitro dissolution studies of fast-dissolving tablets 
were performed by using an USP type II apparatus as 
specified in the USP at 75 rpm, using dissolution media 
(distilled water/ phosphate buffer of pH 6.8) maintained 
at 37±0.5 0C. Aliquots of dissolution medium were with-
drawn at specific time intervals and filtered. Absorption 
of filtered solution was checked by UV spectroscopy, and 
drug content was determined from standard calibration 
curves. The dissolution rate was studied for all formula-
tions designed (Kuchekar, 2001).
Assay method
Twenty tablets were weighed accurately and pow-
dered. Tablet powder equivalent to 10 mg of drug was 
stirred with 100 mL of methanol for 60 minutes, then the 
solution was filtered and treated as stock solution con-
taining 100 μg/mL drug. From this stock solution, further 
dilutions were done for each formulation. Absorbances 
were measured and the concentration of drug in the tablet 
determined using the calibration curve of pure drug in 
methanol, analyzed spectrophotometrically at 238 nm 
using methanol as the blank. 
 (6)
Stability testing
Temperature dependent stability studies were car-
ried out on the optimized batches including DO II, CRP 
II and CCS II. Batches were packed in Alu–Alu pouches 
and stored under the following conditions for a period as 
prescribed by ICH guidelines for accelerated studies in 
stability chambers (Thermolab).
(i) 30 ± 2 o C and RH 65 % ± 5%
(ii) 40 ± 2 o C and RH 75 % ± 5%
The tablets were withdrawn after a period of 7, 14 
days, 1, 2 and 3 months and analyzed for visual defects, 
hardness, friability, disintegration time, thickness, average 
weight and percentage assay (Marais, 2003).
Infrared spectroscopy study of tablets
IR studies were carried out using potassium bromide 
discs. The reference standard was compared with that of 
the formulation.
Data analysis
Phase-solubility studies
The values of apparent stability constant, Ks, be-
tween each drug–carrier combination were computed from 
the phase-solubility profiles, as described below:
  (7)
The values of Gibbs free energy of transfer, ΔGotr, 
of Nifedipine from aqueous solution of the carriers were 
calculated according to the following relationship:
  (8)
Where, So and Ss are the molar solubilities of nifedip-
ine in 1% w/v aqueous solution of the carrier, respectively 
(Naveen, 2007).
Dissolution kinetic modelling
The in vitro drug release data was fitted to four 
models of data treatment for the complexes as follows: 
Zero order:     (9)
First order:    (10)
Higuchi’s model:    (11)
Korsmeyer-Peppas model :    (12)
Where F is the fraction of drug release, k is the 
release constant, t is time and n is diffusional coefficient. 
The value of n is related to the geometrical shape of the 
delivery system and determines the release mechanism 
from various polymeric drug deliveries (Jagdale et al., 
2010). Kinetic modeling was done using PCP Disso soft-
ware (version 3.0).
Dissolution efficiency (DE) studies
The drug release profiles was characterized by 
calculating the DE, which is defined as the area under the 
dissolution curve up to a certain time t, expressed as a 
percentage of the area of the rectangle arising from 100% 
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dissolution at the same time. DE can be calculated by the 
following equation:
  (13)
where y is the percent drug dissolved at time t. A conve-
nient quantification of the effect of the carrier on drug 
dissolution may be obtained by considering log DE/DENIF, 
where DE and DENIF are the dissolution efficiencies of the 
complex and the pure drug, respectively (Cutrignelli et 
al., 2008). DE was calculated using PCP Disso software 
(version 3.0).
Similarity factor (f2)
The in vitro release profile of the pure drug was 
tested under similar conditions to those used for in vitro 
release testing of the test product. The similarity factor 
between the two samples (nifedipine and complexes) was 
determined using the data obtained from the drug release 
studies. The data were analyzed by the following formula.
 (14)
where, n is the number of withdrawal points, Rt is the 
percentage reference dissolved at time point t, and Tt is the 
percentage test product dissolved at time point t. A value 
of 100% for f2 suggests that the test and reference profiles 
were identical. Values between 50 and 100 indicate that the 
dissolution profiles are similar while smaller values imply 
an increase in dissimilarity between the release profiles 
(Jagdale et al., 2009). Similarity factor was calculated 
using PCP Disso software (version 3.0).
RESULTS AND DISCUSSIONS
Phase solubility analysis
The phase solubility curve of nifedipine in the pres-
ence of β-CD is shown in Figure 1. From this curve, it can 
be seen that the solubility of nifedipine increases due to the 
formation of an inclusion complex between nifedipine and 
β-CD. A linear increase in solubility of nifedipine was ob-
served with an increase in concentration of β-CD in water. 
The initial linear ascending part of the solubility diagram is 
generally ascribed to the formation of a 1:1 complex. The 
phase solubility plot showed an AL type solubility curve, 
which indicates that only 1:1 drug-β-CD inclusion complex 
was formed in solution. The apparent stability constant 
(K1:1) for the nifedipine: β-CD complex was calculated from 
the solubility data and found to be 139.23 M-1.
An indication of the process of transfer of nifedipine 
from pure water to aqueous solution of β-CD was obtained 
from the values of Gibbs free energy change. The values 
of Gibbs free energy obtained are shown in Table II. ΔGtr° 
values were all negative for β-CD at various concentra-
tions, indicating the spontaneous nature of nifedipine 
solubilization, and decreased with an increase in its con-
centration, demonstrating that the reaction became more 
favorable as the concentration of β-CD increased.
The negative nature of the Gibbs free energy 
changes (ΔGtr°) (-5.099, -13.31, -21.30, -27.19, -31.84 
and -35.69) for 0.02, 0.04 and 0.06, 0.08, 0.1 moles/ml of 
water respectively) are indicative of the spontaneity of the 
process. The endothermic heats of solution further explain 
the increase in solubility with temperature.
Evaluation complexes
Drug content in drug: b-CD(1:1) complex
Percentage drug content of the complexes are shown 
in Table III and found within the range 73 to 91%. The 
maximum percent drug content was found to be 91.30 % 
in the freeze-dried complex. 
Saturation solubility study
The saturation solubility data for drug and com-
TABLE II - Gibbs free energy of transfer (ΔGtr°) for solubilization 
process of nifedipine in aqueous solutions of β-CD at 37 °C.
Moles of β-CD in water ΔGtr° (KJ/mol)
0 -5.099
0.02 -13.31
0.04 -21.30
0.06 -27.19
0.08 31.84
0.1 -35.69
FIGURE 1- Phase solubility analysis plot for inclusion 
complexes.
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TABLE III - Percentage drug content and saturation solubility of drug: β-CD(1:1) complex
Complexes % Drug Content Solubility (µg/mL) % Increase in Solubility
Drug ………… 7.12 …………..
Physical mixture 73.08 11.20 157.30%
Kneading 84.03 21.60 303.37%
Co-grounding 89.56 17.92 251.68%
Co evaporation 89.87 21.15 297.05%
Melting method 87.23 18.37 258.00%
Freeze-Drying 91.30 28.15 395.36%
Spray Drying 90.56 25.61 359.69%
plexes are given in Table III. The freeze-dried complex 
shows maximum saturation solubility (28.15 µg/mL).
Characterization of nifedipine: b-CD (1:1) 
complex
UV spectroscopic study
The UV spectra of Nifedipine solution in the pres-
ence of β-CD is shown in Figure 2 and Figure 3. There 
was no shift in the λmax of Nifedipine in the presence of 
β-CD. The spectra of complexes showed a diminution in 
FIGURE 2 - Effect of β -CD concentration on UV absorption 
of nifedipine.
FIGURE 3 - Effect of β -CD concentration on UV absorption 
of nifedipine.
absorbance at 238 nm. The induced change in absorbance 
is attributed, primarily, to the formation of an inclusion 
complex. The changes in peak intensity are assumed to 
result from changes in the solvent microenvironment upon 
inclusion of the solute. The observed reduction in peak 
intensity may result from the transfer of the guest molecule 
from water to the CD cavity.
FTIR
FTIR spectroscopy has been used to assess the 
interaction between drug and cyclodextrin molecules in 
the solid state. Figure 4 illustrates the FT-IR spectra of the 
samples under study. The chemical interaction between 
the drug and cyclodextrin often leads to identifiable 
changes in the infrared profile of dispersion. The drug 
spectrum shows prominent peaks at 3331cm -1, 3101 cm-1, 
2931 cm-1, 1689 cm-1, 1624 cm-1, 1528 cm-1, 1380 cm-1, 
1121 cm-1 corresponding to aromatic N-H stretching, 
C-H aromatic stretching, C-H aliphatic stretching, C=O 
stretching in ester, C=C aromatic, -NO2 , -C-CH3 and -C-
O-ester. The prominent peaks of β-CD are at 3326 cm-1, 
2950 cm-1, 1200 cm-1 and 1000 cm-1 corresponding to C-H 
stretching, C-H stretching, C-C-O asymmetric stretching 
and OH bending, respectively. It was noted that the ester 
carbonyl stretching bend of nifedipine shifted from 1689 
down to a lower 1675 cm-1 where this might be attributed 
to intermolecular hydrogen bonding between nifedipine 
and β-CD. Moreover, the absorption band at 3331 cm-1 
ascribed to stretching vibration of the N-H bond in the 
dihydropyridine ring was broadened, slightly shifted or 
nearly disappeared in inclusion complex spectra. Thus, 
IR spectra indicate that the nifedipine molecule is includ-
ed in the β-CD cavity through the dihydropyridine ring. 
The physical mixture of drug with β-CD (1:1) and drug: 
β-CD complexes show the prominent peaks of drug, but 
there was a reduction in peak intensity of drug peaks 
which was obscured by the cyclodextrin peak indicating 
formation of complexes.
S. C. Jagdale, V. N. Jadhav, A. R. Chabukswar, B. S. Kuchekar138
X-ray diffractometry [XRD]
Powder X-ray diffraction spectroscopy has been 
used to assess the degree of crystallinity of the given 
sample. When complexation of drug and β-CD are formed, 
the overall number of crystalline structures is reduced and 
the number of amorphous structures is increased. Thus, 
the final product sample shows fewer, less intense peaks. 
This shows that overall crystallinity of complexes is de-
creased and due to a more amorphous nature, solubility 
is increased. XRD patterns are shown in Figure 5. The 
powder X-ray diffractogram of pure nifedipine showed 
numerous distinctive peaks that indicated a high crystal-
linity. β-CD exhibited characteristic peaks at 10.62, 12.46, 
15.42, 16.98, 20.94, 22.80 due to its crystalline nature. 
The diffractograms of complexes were found to be more 
diffuse compared to drug, while there is no characteristic 
peak i.e. formation of amorphous solid state (inclusion 
complex formation).
DSC
DSC enables the quantitative detection of all pro-
cesses in which energy is required or produced (i.e., 
endothermic or exothermic phase transformations). 
Thermograms for drug and complexes are shown in Fi-
gure 6. DSC studies showed that endothermic peaks for 
pure nifedipine and β-CD were obtained at 175.1°C and 
85.11°C, respectively. The thermogram of drug: β-CD 
(1:1) complex showed complete disappearance of the 
peak of nifedipine and a shift in the endothermic peak of 
β-CD. These findings indicate successful complexation 
with β-CD. Thus, DSC studies confirmed the inclusion 
complexation of drug with β-CD.
FIGURE 4 - IR spectral analysis of drug (a), β-CD (b), physical 
mixture (c) kneading method (d), coevaporation method (e), 
co-grounding (f), spray drying( g), melting method (h), freeze 
drying (i).
FIGURE 5 - X-Ray Diffraction of pure nifedipine (a); pure β-CD 
(b); physical mixture (c); coevaporation complex (d); kneading 
complex (e); cogrounding complex (f); freeze drying complex 
(g); spray drying complex (h); melting complex (i).
FIGURE 6 - DSC study of pure nifedipine(a); pure β-CD (b); 
physical mixture (c); coevaporation complex (d); kneading 
complex (e); cogrounding complex (f); freeze drying complex 
(g); spray drying complex (h); melting complex (i).
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In vitro release profile of complexes
Dissolution profiles of pure nifedipine and complexes 
are shown in Figure 7 and Figure 8. It is evident that the 
complexation technique has improved the dissolution rate of 
nifedipine to a great extent. From in vitro release study (Fi-
gure 7 and Figure 8), it was found that the complex prepared 
as 1:1 by the freeze-drying method showed an improve-
ment in dissolution behavior compared to drug and other 
complexes. This might be due to the inclusion complex 
formation, indicating the improved solubility phenomenon.
Dissolution kinetic modeling
To interpret the release kinetics and mechanism of 
drug release from complexes, the coefficient of determina-
FIGURE 7 - % Drug release of drug and its complexes in 
Distilled Water.
FIGURE 8 - % Drug release of drug and its complexes in 
Phosphate buffer at pH 6.8.
tion was considered as the main parameter for interpreting 
the results. The n values of all formulations are as reported 
in Table IV and Table V. None of the formulations of com-
plexes fit a specific model.
The value of ‘n’ gives an indication of the release 
mechanism; when n = 1, the release rate is independent of 
time (zero-order) (case II transport), n = 0.5 for Fickian 
diffusion and when 0.5 < n <1.0, diffusion and non-Fickian 
transport are implicated. Lastly, when n > 1.0 super case II 
transport is apparent (Korsemeyer et al., 1983). 
DP60 indicates % drug dissolved in 60 minutes, DP120 
% drug dissolved in 120 minutes and DE60 indicates disso-
lution efficiency at 60 minutes for nifedipine and its binary 
systems with carriers in distilled water/phosphate buffer. 
T50% indicates the time required for 50% release of drug. 
The release kinetic analyses of all formulations in 
distilled water are as shown in Table IV. The n value for 
all the formulation was found to be below 0.5 (0.2965 to 
0.4814) thus the release was predominantly by diffusion 
and a non-Fickian transport mechanism. The freeze-dried 
complex showed an n value of 0.3050 indicating diffusion 
as the predominant mechanism of drug release. Freeze-dried 
complex (DE60 = 24.17%) produced the maximum enhance-
ment in dissolution rate. The f2 value of similarity factor 
indicate that the co-grinding method and melting method 
proved similar to the release mechanism of the pure drug, 
with a value greater than 50. For all other formulations, the 
value of the similarity factor was less than 50, thus dissimi-
lar in the release mechanism of drug whereas the dissolution 
profile of the drug was better than that of pure nifedipine. 
Regression analysis was performed and regression values 
‘R2’ were 0.9815 to 0.9977 for different formulations.
The release kinetic analyses of all formulations in 
phosphate buffer are as shown in Table IV. The n value 
for all the formulations was found to be below 0.5 (0.2591 
to 0.4233) thus the release was predominantly by diffu-
sion and a non-Fickian transport mechanism. The freeze-
dried complex showed an n value of 0.2793 indicating 
diffusion as the predominant mechanism of drug release. 
Freeze-dried complex (DE60 = 33.76%) showed the maxi-
mum enhancement in dissolution rate. The f2 value of all 
formulations was less than 50, thus dissimilar in release 
mechanism of drug whereas the dissolution profile of the 
drug was better than that of pure Nifedipine. Regression 
analysis was performed and regression values ‘R2’ were 
0.9716 to 0.9939 for different formulations.
Evaluation of fast-dissolving tablets
To formulate a fast-dissolving tablet of nifedi-
pine, the freeze dried complex was selected based on 
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TABLE V - Dissolution parameter of complexes in phosphate buffer
Complexes
DP
T50%
%DE Best Fit 
mode n R
2 f2DP60 DP120 DE60 DE120
Nif 7.7549 10.828 387.09 6.48 9.04 Matrix 0.4233 0.9898 -
Kn 34.86166 39.02372 86.05 27.01 33.31 Peppas 0.2591 0.9827 33.01
COE 37.63636 45.78261 79.72 27.01 33.32 Peppas 0.2591 0.9827 29.94
COG 33.083 39.77075 90.68 25.85 32.49 Peppas 0.2869 0.9920 33.83
MELT 29.49012 35.14625 101.72 23.68 29.19 Peppas 0.2668 0.9951 36.95
PM 24.51344 28.63636 122.39 19.57 23.88 Peppas 0.2811 0.9939 43.40
FD 42.68775 55.38735 70.29 33.76 42.08 Peppas 0.2793 0.9842 26.18
SPD 50.40711 37.63636 59.52 29.45 37.71 Peppas 0.2626 0.9716 29.17
TABLE IV - Dissolution parameter of complexes in distilled water
Complexes
DP
T50%
%DE Best Fit 
mode N R
2 f2DP60 DP120 DE60 DE120
Nifedipine 6.27 8.6940 478.46 5.55 7.46 Matrix 0.4814 0.9897 ------
Kn 25.95059 28.0956 115.60 19.12 24.11 Peppas 0.3460 0.9924 41.60
COE 24.52767 35.25296 122.34 20.07 25.49 Peppas 0.3104 0.9855 39.12
COG 19.56166 23.41779 153.37 15.42 19.39 Peppas 0.3387 0.9960 48.54
Melt 18.53715 22.283 161.89 10.84 14.62 Matrix 0.4177 0.9944 50.91
PM 12.48972 17.58024 240.38 9.65 13.23 Matrix 0.4590 0.9977 63.90
FD 29.09881 43.36364 103.12 24.17 31.64 Peppas 0.3050 0.9815 32.98
SPD 26.67273 38.81028 112.48 21.74 27.49 Peppas 0.2965 0.9830 36.67
its saturation solubility and in-vitro dissolution perfor-
mance. Three different superdisintegrants, dosion (DO), 
crospovidone(CRP), and croscarmellose sodium (CCS) 
with different concentrations (6%, 8%, 10%) were tried 
in order to achieve fast dispersion of tablets.
Micromeritic properties of tablet powder were cal-
culated and tabulated in Table VI. Bulk Density, tapped 
density, Carr’s index and Hausner Ratio were found to be 
0.6774 gm/cm3±0.0170, 0.8111 gm/cm3±0.0324, 16.41 
%±2.20, and 1.1971±0.0313, respectively. Hausner Ra-
tio was found to be less than 1.25, evidencing good flow. 
Carr’s index was in the 12.82-18.91 range; hence was fair 
to passable.
All the formulations exhibited a yellow color, were 
odorless, flat circular in shape and had a smooth surface. 
The prepared tablets were evaluated for hardness, friabil-
ity, weight variation, thickness, in vitro disintegration time, 
water absorption ratio and % assay, with data shown in 
Table VII. Hardness and friability of all formulations were 
within acceptable limits. Hardness of tablets prepared by 
direct compression was 3.19-3.63 kg/cm2. The friability 
of all formulations was found to be less than 1.0 % and 
hence the tablets with lower friability do not break dur-
ing handling on machines and or shipping. The average 
weight of the fast-dissolving tablets prepared by the direct 
compression method was 257-259 mg. Thickness of tablet 
was found to lie within the range 3.16±0.40 mm.
The % drug content of the prepared tablets was in 
the range 97.01 to 98.55 % per tablet. Low values of stan-
dard (0.15% - 0.61%) deviation in terms of drug content 
indicate uniform drug distribution and application of all 
methods for the preparation of complexes with high con-
tent uniformity.
Disintegration time is very important for fast-dissolv-
ing tablet with a desired value of less than 3 min (Korse-
meyer et al., 1983). Disintegration time of the prepared 
fast-dissolving tablet was in the range 0.51 to 3.5 min.
Figure 9 and Figure10 show that the formulations 
DO II, CRP II and CCS II exhibited maximum release in 
distilled water and in phosphate buffer at pH 6.8 compared 
to other formulations. Hence, these three formulations 
were selected for stability study. 
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TABLE VI - Physical characterization of nifedipine blend
Formulation Bulk Density (gm/cm3)
Tapped Density 
(gm/cm3)
Carr’s Index 
(%)
Hausner 
Ratio
Control 0.6666 0.7640 12.820 1.1470
DO I 0.6666 0.7878 15.384 1.1818
DO II 0.6842 0.8125 15.789 1.1875
DO III 0.6666 0.8125 17.948 1.2187
PGS I 0.6842 0.8387 18.421 1.2258
PGS II 0.6842 0.8387 18.421 1.2258
PGS III 0.6666 0.8125 17.948 1.2187
CRP I 0.7027 0.8125 13.513 1.1562
CRP II 0.6842 0.8387 18.421 1.2258
CRP III 0.7027 0.8666 18.918 1.2333
SSG I 0.6666 0.8125 17.948 1.2187
SSG II 0.6842 0.8387 18.421 1.2258
SSG III 0.7647 0.8965 14.705 1.1724
CCS I 0.6842 0.8387 18.4210 1.2258
CCS II 0.6666 0.8125 17.9487 1.2187
CCS III 0.65 0.7647 15 1.1764
TABLE VII - Evaluation of fast-dissolving tablets
Formulation Hardness** (kg/cm2)
Friability 
(%)
Thickness** 
(mm)
D.T
(min)**
Average weight 
(mg) *
Water 
absorption ratio % Assay
Control 3.19±0.07 0.70 3.16±0.40 3.5±0.127 257±0.63 168.4±0.1 97.3±0.23
DO I 3.22±0.14 0.76 3.02±0.01 1.55±0.04 257.83±0.98 135.4±0.9 98.28±0.25
DO II 3.23±0.11 0.63 3.33±0.51 1.12±0.02 257±0.6324 124.1±0.2 98.5±0.43
DO III 3.19±0.07 0.72 3.5±0.54 1.25±0.03 257.66±0.81 138.0±1.6 97.2±0.55
PGS I 2.9±1.31 0.76 3.3±0.02 3.2±0.012 255.6±0.529 135.4±0.9 98.28±0.25
PGS II 3.2±1.06 0.63 3.4±0.04 3.10±0.04 255.2±1.058 95.0±1.21 98.07±0.61
PGS III 3.4±0.89 0.72 3.1±0.02 2.15±0.05 256.83±0.59 148.6±0.4 97.45±0.17
CRP I 3.3±0.032 0.78 3.3±0.05 1.60±0.57 258.06±0.70 152.0±0.6 98.59±0.29
CRP II 3.20±0.10 0.79 3.2±0.53 0.51±0.07 258.93±0.90 90.4±0.84 97.01±0.15
CRP III 3.63±0.15 0.62 3.2±0.22 0.72±0.57 259.33±0.57 98.2±0.12 97.12±0.43
SSG I 3.62±0.15 0.75 3.1±0.02 3.34±0.03 257.16±1.04 90.4±0.84 97.01±0.15
SSG II 3.53±0.15 0.82 3.02±0.01 2.4±0.026 256.83±0.76 98.2±0.12 97.12±0.43
SSG III 3.2±0.100 0.85 3.02±0.02 2±0.05 255.5±0.500 122.4±0.2 98.15±0.21
CCS I 3.23±0.15 0.78 3.1±0.02 2.15±0.01 257.66±0.57 122.4±0.2 98.15±0.21
CCS II 3.36±0.05 0.64 3.02±0.01 1.30±0.57 259.70±0.35 95.0±1.21 98.07±0.61
CCS III 3.46±0.01 0.68 3.02±0.02 1.45±0.02 258.43±0.52 148.6±0.4 97.45±0.17
* average ± sd, n = 20, ** average ± sd, n = 6. 
Figure 11 shows the effect of superdisintegrant on 
D.T. Doshion is ion exchange resins. Doshion shows a 
decrease in D.T. as concentration increases. Hence 8% 
Doshion was selected. Crospovidone shows a decrease in 
D.T. as concentration increases. This was because CRP 
exhibits a capillary mechanism of disintegration. When 
in contact with water it replaces the air absorbed by par-
ticles. This weakens the intermolecular bond and breaks 
the tablet into smaller particles. As the concentration of 
CRP increased, the number of capillaries also increased 
thus increasing the channeling of water. Therefore, the 
rate of liberation to primary particles increases. Hence, 
8% CRP was selected. CCS showed a decrease in D.T. as 
concentration increases. Hence, 8% CCS was selected.
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Stability testing
From the stability data in Table VIII and Table IX 
for batches DO II, CRP II and CCS III, it can be concluded 
that there were no significant changes in any parameters, 
and optimized batches i.e. DO II, CRP II and CCS II are 
therefore deemed stable. Hence, this product can be kept 
for a period of one year or more.
TABLE VIII - Stability testing - i) 30 ± 1 OC and RH 65 % ± 5%
Formulation Parameter Initial 30 ºC/ 65% RH 7 days
30 ºC/ 65% RH 
14 days
30 ºC/ 65% RH 
1 Month
30 ºC/ 65% RH 
2 Months
30 ºC/ 65% RH 
3 Months
DO II Hardness ** (kg/cm2) 3.23±0.11 3.2±0.19 3.3±0.57 3.13±0.51 3.15±0.47 3.1±0.19
Friability (%) 0.63 0.68 0.70 0.72 0.68 0.71
Thickness** (mm) 3.33±0.51 3±0.02 3.3±0.22 3.3±0.03 3.1±0.04 3.3±0.02
D.T (min) ** 1.12±0.05 1.12±0.07 1.15±0.3 1.15±0.4 1.16±0.20 1.14±0.5
Assay % 98.5±0.43 98.2±0.43 97.5±0.43 97.1±0.43 98.45±0.43 98.5±0.43
Average weight (mg) * 257±0.6324 256.30±0.384 257.22±0.12 257±0.12 257.55±0.143 257.70±0.60
CRP II Hardness ** (kg/cm2) 3.20±0.10 3.36±0.08 3.32±0.05 3.27±0.05 3.44±0.19 3.11±0.072
Friability (%) 0.79 0.74 0.65 0.68 0.72 0.65
Thickness** (mm) 3.2±0.53 3.21±0.02 3.43±0.05 3.12±0.01 3.14±0.02 3.15±0.06
D.T. (min) ** 0.51±0.07 0.55±0.02 0.54±0.08 0.50±0.09 0.58±0.01 0.53±0.02
Assay % 97.01±0.15 97.15±0.14 98.29±0.17 97.20±0.11 98.38±0.52 98.40±0.25
Average weight (mg) * 258.93±0.90 257.13±0.90 257.13±0.12 256.33±0.15 256.43±0.52 255.43±0.5
CCS II Hardness **(kg/cm2 ) 3.36±0.05 3.14±0.152 3.16±0.0346 3.35±0.015 3.20±0.024 3.45±0.013
Friability (%) 0.64 0.70 0.68 0.65 0.69 0.70
Thickness** (mm) 3.02±0.01 3.1±0.03 3.2±0.100 3.03±0.057 3.1±0.10 3.3±0.04
D.T (min) ** 1.30±0.577 1.35±0.026 1.36±0.01 1.38±0.015 1.38±0.025 1.40±0.014
Assay % 98.07±0.61 97.21±0.15 98.89±0.41 97.37±0.24 97.45±0.52 98.89±0.15
Average weight (mg) * 259.70±0.35 257.16±0.24 258±1.00 258±1.50 257.18±1.23 258±1.12
* average ± sd, n = 10, ** average ± sd, n = 6.
FIGURE 9 - % Drug release from tablet in Phosphate buffer at 
pH 6.8.
FIGURE 10 - % Drug release from tablet in Distilled water.
FIGURE 11- Effect of concentration of superdisintegrants.
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TABLE IX - Stability testing - ii) 40 ± 2 O C and RH 75 % ± 5%
Formulation Parameter
40 ºC/ 75% RH 
7 days
40 ºC/ 75% RH 
14 days
40 ºC/ 75% RH 
1 Month
40 ºC/ 75% RH 
2 Months
40 ºC/ 75% RH 
3 Months
DO II Hardness ** (kg/cm2 ) 3.23±0.11 3.1±0.19 3.14±0.57 3.24±0.51 3.24±0.47
Friability (%) 0.63 0.65 0.75 0.71 0.70
Thickness** (mm) 3.33±0.51 3.01±0.02 3.2±0.22 3.1±0.03 3.2±0.04
D.T.(min) ** 1.12±0.05 1.12±0.17 1.14±0.2 1.20±0.14 1.24±0.20
Assay % 98.5±0.43 97.2±0.13 98.5±0.13 97.1±0.52 98.15±0.43
Average weight (mg) * 257±0.6324 257.24±0.384 257.34±0.12 258.04±0.12 256.55±0.143
CRP II Hardness ** (kg/cm2 ) 3.20±0.10 3.27±0.08 3.14±0.42 3.27±0.14 3.14±0.19
Friability (%) 0.79 0.84 0.80 0.70 0.75
Thickness** (mm) 3.2±0.53 3.24±0.02 3.13±0.14 3.22±0.07 3.14±0.05
D.T. (min) ** 0.51±0.07 0.58±0.02 0.58±0.08 0.55±0.02 0.57±0.01
Assay % 97.01±0.15 98.15±0.14 97.12±0.15 97.20±0.24 98.38±0.52
Average weight (mg) * 258.93±0.9018 257.87±0.90 256.23±0.64 258.25±0.127 257.12±0.52
CCS II Hardness ** (kg/cm2 ) 3.36±0.05 3.24±0.152 3.17±0.0457 3.27±0.0247 3.25±0.014
Friability (%) 0.64 0.70 0.80 0.75 0.72
Thickness** (mm) 3.02±0.01 3.1±0.03 3.2±0.100 3.13±0.127 3.3±0.26
D.T.(min) ** 1.30±0.577 1.35±0.026 1.34±0.01 1.40±0.015 1.38±0.025
Assay % 98.07±0.61 97.21±0.15 97.27±0.41 98.37±0.25 98.15±0.18
Average weight (mg) * 259.70±0.356 258.16±0.24 257±1.24 256.04±0.4 258.20±0.54
* average ± sd, n = 10, ** average ± sd, n = 6.
FIGURE 12 - I.R of Nifedipine (a), DO II (b), CRP II (c) and CCS II (d).
Infrared Spectroscopy Study of Tablet
From the above spectrum (Figure 12), it can be seen 
that the major peaks of the drug were unchanged, i.e. there 
was no interaction between drug and excipients for DO II, 
CRP II or CCS II.
CONCLUSION
The dissolution rate of nifedipine was successfully 
enhanced by the cyclodextrin complexation technique. 
The method of preparing complexes played a key role in 
enhancing the dissolution rate. The enhancement of the 
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dissolution rate helped toward providing rapid onset of ac-
tion of the drug. Fast-dissolving tablet also helped toward 
the enhancement of dissolution rate. 
Based on the findings of various tests it can be con-
cluded that, 
1. Inclusion complexes significantly improved disso-
lution profiles.
2. Inclusion complexes of nifedipine produced by 
different methods exhibited the following order of 
enhanced solubility: freeze-drying > spray drying > 
kneading > coevaporation > melting > co-grounding 
> physical mixture. 
3. X- Ray diffraction, differential scanning calorimetric 
data and IR and UV spectral analysis results indica-
ted no probable interaction between drug and β-CD. 
4. The inclusion complexes with cyclodextrin prepared 
by the freeze-drying method showed highest solubi-
lity (28.15 µg/ ml) and a fast dissolution profile. 
5. These investigations demonstrated that it is possible 
to prepare fast-dissolving tablets by a direct com-
pression method. 
6. Disintegration time decreased with increased con-
centration of superdisintegrants. Formulations of 
doshion (8 %), crospovidone (8 %) and croscar-
mellose sodium (8 %) showed faster disintegration 
and maximum percent of drug release.
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